Which infection would be prevented by administering the Gardasil vaccine to a male patient?

GARDASIL 9 is a vaccine indicated in females 9 through 45 years of age for the prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) Types 16, 18, 31, 33, 45, 52, and 58; cervical, vulvar, vaginal, and anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.

GARDASIL 9 is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.

The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

GARDASIL 9 does not eliminate the necessity for vaccine recipients to undergo screening for cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers as recommended by a health care provider.

GARDASIL 9 has not been demonstrated to provide protection against diseases caused by:

  • HPV types not covered by the vaccine
  • HPV types to which a person has previously been exposed through sexual activity

Not all vulvar, vaginal, anal, oropharyngeal and other head and neck cancers are caused by HPV, and GARDASIL 9 protects only against those vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58.

GARDASIL 9 is not a treatment for external genital lesions; cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers; or cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VaIN), or anal intraepithelial neoplasia (AIN).

Vaccination with GARDASIL 9 may not result in protection in all vaccine recipients.

Close

Select Safety Information for GARDASIL 9

GARDASIL 9 is contraindicated in individuals with hypersensitivity, including severe allergic reactions to yeast, or after a previous dose of GARDASIL 9 or GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant].

GARDASIL 9 is contraindicated in individuals with hypersensitivity, including severe allergic reactions to yeast, or after a previous dose of GARDASIL 9 or GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant].

Because vaccinees may develop syncope, sometimes resulting in falling with injury, observation for 15 minutes after administration is recommended. Syncope, sometimes associated with tonic-clonic movements and other seizure-like activity, has been reported following HPV vaccination. When syncope is associated with tonic-clonic movements, the activity is usually transient and typically responds to restoring cerebral perfusion.

Safety and effectiveness of GARDASIL 9 have not been established in pregnant women.

The most common (≥10%) local and systemic adverse reactions in females were injection-site pain, swelling, erythema, and headache. The most common (≥10%) local and systemic reactions in males were injection-site pain, swelling, and erythema.

The duration of immunity of GARDASIL 9 has not been established.

Dosage and Administration for GARDASIL 9

GARDASIL 9 should be administered intramuscularly in the deltoid or anterolateral area of the thigh.

  • For individuals 9 through 14 years of age, GARDASIL 9 can be administered using a 2-dose or 3-dose schedule. For the 2-dose schedule, the second dose should be administered 6–12 months after the first dose. If the second dose is administered less than 5 months after the first dose, a third dose should be given at least 4 months after the second dose. For the 3-dose schedule, GARDASIL 9 should be administered at 0, 2 months, and 6 months.
  • For individuals 15 through 45 years of age, GARDASIL 9 is administered using a 3-dose schedule at 0, 2 months, and 6 months.

Before administering GARDASIL 9, please read the Prescribing Information. The Patient Information also is available.

HPV vaccine: Who needs it, how it works

Who needs the HPV vaccine? How many doses? What about side effects? Get answers to these questions and more.

By Mayo Clinic Staff

Most cervical cancers are associated with human papillomavirus (HPV), a sexually transmitted infection. Widespread immunization with the HPV vaccine could reduce the impact of cervical cancer and other cancers caused by HPV worldwide. Here's what you need to know about the HPV vaccine.

What does the HPV vaccine do?

Various strains of HPV spread through sexual contact and are associated with most cases of cervical cancer. Gardasil 9 is an HPV vaccine approved by the U.S. Food and Drug Administration and can be used for both girls and boys.

This vaccine can prevent most cases of cervical cancer if the vaccine is given before girls or women are exposed to the virus. This vaccine can also prevent vaginal and vulvar cancer. In addition, the vaccine can prevent genital warts, anal cancers, and mouth, throat, head and neck cancers in women and men.

In theory, vaccinating boys against the types of HPV associated with cervical cancer might also help protect girls from the virus by possibly decreasing transmission.

Who is the HPV vaccine for and when should it be given?

The Centers for Disease Control and Prevention (CDC) recommends that the HPV vaccine be given to girls and boys between ages 11 and 12. It can be given as early as age 9. It's ideal for girls and boys to receive the vaccine before they have sexual contact and are exposed to HPV. Research has shown that receiving the vaccine at a young age isn't linked to an earlier start of sexual activity.

Once someone is infected with HPV, the vaccine might not be as effective. Also, response to the vaccine is better at younger ages than it is at older ages.

The CDC recommends that all 11- and 12-year-olds receive two doses of HPV vaccine at least six months apart. Younger adolescents ages 9 and 10 and teens ages 13 and 14 also can receive vaccination on the two-dose schedule. Research has shown that the two-dose schedule is effective for children under 15.

Teens and young adults who begin the vaccine series later, at ages 15 through 26, should receive three doses of the vaccine.

The CDC recommends catch-up HPV vaccinations for all people through age 26 who aren't adequately vaccinated.

The U.S. Food and Drug Administration recently approved the use of Gardasil 9 for males and females ages 9 to 45. If you're age 27 to 45, discuss with your doctor whether he or she recommends that you get the HPV vaccine.

Who should not get the HPV vaccine?

The HPV vaccine isn't recommended for pregnant women or people who are moderately or severely ill. Tell your doctor if you have any severe allergies, including an allergy to yeast or latex. Also, if you've had a life-threatening allergic reaction to any component of the vaccine or to a previous dose of the vaccine, you shouldn't get the vaccine.

Does the HPV vaccine offer benefits if you're already sexually active?

Yes. Even if you already have one strain of HPV, you could still benefit from the vaccine because it can protect you from other strains that you don't yet have. However, none of the vaccines can treat an existing HPV infection. The vaccines protect you only from specific strains of HPV you haven't been exposed to already.

Does the HPV vaccine carry any health risks or side effects?

The HPV vaccine has been found to be safe in many studies.

Overall, the effects are usually mild. The most common side effects of HPV vaccines include soreness, swelling or redness at the injection site.

Sometimes dizziness or fainting occurs after the injection. Remaining seated for 15 minutes after the injection can reduce the risk of fainting. Headaches, nausea, vomiting, fatigue or weakness also may occur.

The CDC and the FDA continue to monitor the vaccines for unusual or severe problems.

Is the HPV vaccine required for school enrollment?

The HPV vaccine is part of the routine childhood vaccines schedule. Whether a vaccine becomes a school enrollment requirement is decided on a state-by-state basis.

Do women who've received the HPV vaccine still need to have Pap tests?

Yes. The HPV vaccine isn't intended to replace Pap tests. Routine screening for cervical cancer through regular Pap tests beginning at age 21 remains an essential part of preventive health care.

HPV spreads through sexual contact — oral, vaginal or anal. To protect yourself from HPV, use a condom every time you have sex. In addition, don't smoke. Smoking raises the risk of cervical cancer.

To detect cervical cancer in the earliest stages, see your doctor for regular Pap tests beginning at age 21. Seek prompt medical attention if you notice any signs or symptoms of cervical cancer — vaginal bleeding after sex, between periods or after menopause, pelvic pain, or pain during sex.

From Mayo Clinic to your inbox

Sign up for free, and stay up to date on research advancements, health tips and current health topics, like COVID-19, plus expertise on managing health.

To provide you with the most relevant and helpful information, and understand which information is beneficial, we may combine your email and website usage information with other information we have about you. If you are a Mayo Clinic patient, this could include protected health information. If we combine this information with your protected health information, we will treat all of that information as protected health information and will only use or disclose that information as set forth in our notice of privacy practices. You may opt-out of email communications at any time by clicking on the unsubscribe link in the e-mail.

Sept. 18, 2021

  1. Human papillomavirus (HPV) vaccination: What everyone should know. Centers for Disease Control and Prevention. https://www.cdc.gov/vaccines/vpd/hpv/public/index.html. Accessed May 20, 2021.
  2. HPV vaccine schedule and dosing. Centers for Disease Control and Prevention. https://www.cdc.gov/hpv/hcp/schedules-recommendations.html?CDC_. Accessed May 20, 2021.
  3. Human papillomavirus vaccination. https://www.uptodate.com/contents/search. Accessed May 20, 2021.
  4. Genital HPV infection – CDC fact sheet. Centers for Disease Control and Prevention. https://www.cdc.gov/std/hpv/stdfact-hpv.htm. Accessed May 20, 2021.
  5. Human papillomarivirus 9-valent vaccine, recombinant. IBM Micromedex. https://www.micromedexsolutions.com. Accessed May 20, 2021.
  6. Cervical cancer screening (PDQ) – Patient version. National Cancer Institute. https://www.cancer.gov/types/cervical/patient/cervical-screening-pdq. Accessed May 24, 2021.
  7. Vaccines at 11 to 12 years. Centers for Disease Control and Prevention. https://www.cdc.gov/vaccines/parents/by-age/years-11-12.html. Accessed May 24, 2021.

See more In-depth

See also

  1. Cervical cancer
  2. What is cervical cancer? A Mayo Clinic expert explains
  3. Cervical cancer FAQs
  4. Cervical dysplasia: Is it cancer?
  5. Common warts
  6. Genital warts
  7. Gynecologic Cancers
  8. Head and Neck Cancer
  9. HPV infection
  10. HPV infection: A cause of cancer in men?
  11. Infographic: HPV Related Oral Cancers
  12. Mayo Clinic Minute: Why and when children should be vaccinated
  13. Pap smear
  14. Pap smear: Do I need one if I'm a virgin?
  15. Pap smear: Still needed after hysterectomy?
  16. Plantar warts
  17. STD testing
  18. Stop warts from spreading
  19. Vaccine guidance from Mayo Clinic

.

Which symptoms would the nurse expect patients having acute cystitis prostatitis or urethritis to have in common?

Both cystitis and urethritis may present with pain or difficulty on urination (dysuria), frequency, urgency, and/or suprapubic pain or heaviness. A careful history may help differentiate between the two diseases. Urethritis may be associated with urethral discharge or meatal pruritus.

Which medication would the nurse administer to a patient who has syphilitic chancre?

Penicillin G administered intramuscularly (IM) or intravenously (IV) is the preferred drug for treating all stages of syphilis.

Which change in the breast is seen in a patient who has reached menopause?

During menopause, decreases in circulating estrogen and progesterone cause the lobular tissue to undergo involution[3]. At this time, connective tissue becomes more dense and adipose tissue gradually replaces breast parenchyma.